We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

85 hedge funds and large institutions have $203M invested in Concert Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 24 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

401% more call options, than puts

Call options by funds: $1.12M | Put options by funds: $224K

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

17% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 24

6% more funds holding

Funds holding: 80 → 85 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

11% less capital invested

Capital invested by funds: $227M → $203M (-$24.5M)

Holders
85
Holders Change
+5
Holders Change %
+6.25%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
28
Reduced
24
Closed
13
Calls
$1.12M
Puts
$224K
Net Calls
+$898K
Net Calls Change
-$113K

Top Buyers

Rank Fund Capital Flow
1
KCM
Kynam Capital Management
New Jersey
+$14.4M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.63M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$2.86M
4
BlackRock
BlackRock
New York
+$2.16M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.42M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$14.4M
2
EI
EAM Investors
California
-$5.93M
3
AG
Artal Group
Luxembourg
-$3.84M
4
EGI
EAM Global Investors
California
-$2.26M
5
Morgan Stanley
Morgan Stanley
New York
-$1.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$2.44M +$49.3K +9,369 +2%
Two Sigma Advisers
27
Two Sigma Advisers
New York
$2.16M -$619K -117,800 -24%
Connor, Clark & Lunn Investment Management (CC&L)
28
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.7M -$51.3K -9,763 -3%
JP Morgan Chase
29
JP Morgan Chase
New York
$1.6M +$983K +186,915 +214%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$1.4M +$1.07M +202,781 +542%
PVI
31
Pura Vida Investments
New York
$1.21M +$1.09M +206,525 New
IBT
32
International Biotechnology Trust
United Kingdom
$1.17M – – –
Citigroup
33
Citigroup
New York
$1.13M +$386K +73,373 +61%
BCM
34
Bridgeway Capital Management
Texas
$865K – – –
State Street
35
State Street
Massachusetts
$823K +$107K +20,300 +17%
Northern Trust
36
Northern Trust
Illinois
$753K -$2.32K -442 -0.3%
Two Sigma Investments
37
Two Sigma Investments
New York
$704K -$1.3M -247,347 -67%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$665K +$599K +113,848 New
CAM
39
ClariVest Asset Management
California
$603K -$7.89K -1,500 -1%
Ensign Peak Advisors
40
Ensign Peak Advisors
Utah
$516K – – –
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$509K +$454K +86,329 +9,777%
CANY
42
Caxton Associates (New York)
New York
$491K -$211K -40,122 -32%
Walleye Capital
43
Walleye Capital
New York
$435K +$392K +74,548 New
BDF
44
Black Diamond Financial
Maryland
$415K – – –
KIC
45
Kensington Investment Counsel
California
$342K -$95.7K -18,202 -24%
RC
46
RBF Capital
California
$287K -$83K -15,781 -24%
Qube Research & Technologies (QRT)
47
Qube Research & Technologies (QRT)
United Kingdom
$275K +$70.5K +13,399 +40%
CSS
48
Cubist Systematic Strategies
Connecticut
$270K -$141K -26,901 -37%
BC
49
BIT Capital
Germany
$228K -$99.9K -19,000 -33%
6CM
50
683 Capital Management
New York
$222K +$200K +38,058 New
1
2
3 4

CNCE Hedge Fund Activity: Q4 2022 in Review

85 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2022, worth a combined $203M — down 11% from $227M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CNCE positions and 13 closed out — a net gain of 5 holders — while 28 added to existing stakes and 24 trimmed.

The largest buyer was Kynam Capital Management, adding an estimated $14.4M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $14.4M sold.

  • 85 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2022, up from 80 in Q3 2022.
  • Funds reported $203M of Concert Pharmaceuticals, Inc. stock for Q4 2022, down 11% quarter-over-quarter.
  • 18 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2022 and 13 closed out, a net change of +5 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q4 2022 was Kynam Capital Management, an estimated $14.4M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q4 2022 was Perceptive Advisors, an estimated $14.4M sold.

Based on aggregated 13F filings for Q4 2022.